MAIA has 36-month beta value of 0.52. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for MAIA is 15.48M, and currently, short sellers hold a 5.46% ratio of that float. The average trading volume of MAIA on April 22, 2024 was 325.40K shares.
MAIA) stock’s latest price update
MAIA Biotechnology Inc (AMEX: MAIA)’s stock price has gone rise by 9.69 in comparison to its previous close of 1.96, however, the company has experienced a -2.49% decrease in its stock price over the last five trading days. Business Wire reported 2024-04-05 that CHICAGO–(BUSINESS WIRE)–MAIA Biotechnology to Present at Two Investor Conferences in April 2024.
MAIA’s Market Performance
MAIA Biotechnology Inc (MAIA) has seen a -2.49% fall in stock performance for the week, with a 30.30% gain in the past month and a 67.97% surge in the past quarter. The volatility ratio for the week is 9.79%, and the volatility levels for the past 30 days are at 14.40% for MAIA. The simple moving average for the past 20 days is -5.73% for MAIA’s stock, with a 23.72% simple moving average for the past 200 days.
MAIA Trading at 20.92% from the 50-Day Moving Average
After a stumble in the market that brought MAIA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -46.12% of loss for the given period.
Volatility was left at 14.40%, however, over the last 30 days, the volatility rate increased by 9.79%, as shares surge +10.82% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +51.41% upper at present.
During the last 5 trading sessions, MAIA fell by -2.49%, which changed the moving average for the period of 200-days by -5.29% in comparison to the 20-day moving average, which settled at $2.29. In addition, MAIA Biotechnology Inc saw 83.76% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MAIA starting from Smith Stan, who purchase 170,940 shares at the price of $1.17 back on Mar 14 ’24. After this action, Smith Stan now owns 857,568 shares of MAIA Biotechnology Inc, valued at $200,000 using the latest closing price.
Louie Ngar Yee, the Director of MAIA Biotechnology Inc, purchase 170,940 shares at $1.17 during a trade that took place back on Mar 14 ’24, which means that Louie Ngar Yee is holding 1,147,524 shares at $200,000 based on the most recent closing price.
Stock Fundamentals for MAIA
The total capital return value is set at -6.7. Equity return is now at value -440.12, with -201.88 for asset returns.
Currently, EBITDA for the company is -15.86 million with net debt to EBITDA at 0.32. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.53.
Conclusion
To put it simply, MAIA Biotechnology Inc (MAIA) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
